Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex- and menopause-specific inverse associations between metabolic dysfunction-associated steatotic liver disease and serum lipoprotein(a) concentrations: evidence from SHIP and UK Biobank.

Cardiovascular diabetology·2026
Same author

CMR Reveals the Influence of Trigger and Classification on the Myocardial Tissue Response in Takotsubo Syndrome.

Circulation. Cardiovascular imaging·2026
Same author

Killip class at presentation and immediate versus staged multivessel PCI in patients with STEMI.

Scientific reports·2026
Same author

Associations of sphingosine-1-phosphate with thyroid function and structure: a cross-sectional population-based study.

European thyroid journal·2026
Same author

Partner valves: role of a prospective device selection strategy using ACURATE and SAPIEN 3 as complementary devices in transcatheter aortic valve implantation.

Frontiers in cardiovascular medicine·2026
Same author

Subcutaneous Adipose Tissue as a Metabolic Mirror: Transcriptomic Insights Into Glycaemic Dysregulation.

European journal of clinical investigation·2026

Related Experiment Video

Updated: Jun 19, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Beta-Blockers After Myocardial Infarction With Preserved and Mildly Reduced Ejection Fraction: A Meta-Analysis With

Michele Maremmani1, Paolo Gianfico2, Christian Templin3,4

  • 1Department of Cardiology, Sant'Andrea Hospital, La Spezia, Italy.

European Journal of Clinical Investigation
|June 18, 2026
PubMed
Summary

Beta-blockers show no benefit for myocardial infarction (MI) patients with preserved ejection fraction, with conclusive evidence of futility. However, they reduced major adverse cardiovascular events in those with mildly reduced ejection fraction, requiring further study.

Keywords:
Beta‐blockersmyocardial infarctionpreserved ejection fractionreperfusion eratrial sequential analysis

Related Experiment Videos

Last Updated: Jun 19, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Beta-blockers are standard therapy post-myocardial infarction (MI).
  • Their efficacy may vary based on left ventricular ejection fraction (LVEF).
  • Evidence on beta-blocker use across LVEF strata needs further evaluation.

Purpose of the Study:

  • To assess beta-blocker efficacy in post-MI patients stratified by LVEF.
  • To evaluate the conclusiveness of existing evidence using Trial Sequential Analysis (TSA).

Main Methods:

  • Systematic search of PubMed, Embase, and ClinicalTrials.gov for relevant RCTs.
  • Time-to-event meta-analysis and Mantel-Haenszel method for risk ratios (RR).
  • LVEF-stratified analyses and TSA to determine statistical significance and futility.

Main Results:

  • Beta-blockers did not reduce the primary endpoint or mortality in post-MI patients (HR 0.92, 95% CI 0.85-1.01).
  • No significant reduction in death or MACE observed in patients with preserved LVEF (≥50%), with TSA confirming futility.
  • A significant reduction in MACE was noted in patients with mildly reduced LVEF (40%-49%) (RR 0.74, 95% CI 0.58-0.94), though TSA did not confirm conclusiveness.

Conclusions:

  • Beta-blockers offer no benefit in post-MI patients with preserved LVEF, with conclusive evidence of futility.
  • Therapy showed a potential benefit in reducing MACE for patients with mildly reduced LVEF.
  • Further adequately powered randomized trials are needed to confirm findings in the mildly reduced LVEF group.